Affymax(R) to Present at Acumen BioFin 4th Annual Global Health Care Conference.PALO ALTO Palo Alto, city, California Palo Alto (păl`ō ăl`tō), city (1990 pop. 55,900), Santa Clara co., W Calif.; inc. 1894. Although primarily residential, Palo Alto has aerospace, electronics, and advanced research industries. , Calif. -- Affymax, Inc. (Nasdaq:AFFY) today announced that Paul B. Cleveland, the company's chief financial officer and executive vice president, Corporate Development, will present at the Acumen BioFin 4th Annual Global Health Care Conference on Monday, May 14, 2007 at 4:20 p.m. in Monte Carlo Monte Carlo (môNtā` kärlō`), town (1982 pop. 13,150), principality of Monaco, on the Mediterranean Sea and the French Riviera. . A live webcast of the presentation will be available on the Investors section of the company's website at www.affymax.com. A replay will also be available for 30 days following the presentation. About Affymax, Inc. Affymax, Inc. is a biopharmaceutical company developing novel peptide-based drugs to improve the treatment of serious and often life-threatening conditions. Affymax's lead product candidate, Hematide[TM], is currently in Phase 2 clinical trials phase 2 clinical trial Phase 2 study. See Phase study. for the treatment of anemia associated with chronic kidney disease Chronic kidney disease (CKD), also know as chronic renal disease, is a progressive loss of renal function over a period of months or years through five stages. Each stage is a progression through an abnormally low and progressively worse glomerular filtration rate, which is and cancer. For additional information, please visit www.affymax.com. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion